H-Index
79
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
15%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 1643-3750

Effects of Montelukast in an Experimental Model of Acute Pancreatitis

Serkan Angı, Hüseyin Eken, Erol Kılıc, Oktay Karaköse, Gürhan Balci, Erkan Somuncu

Department of General Surgery, Ondokuz Mayıs University, Samsun, Turkey

Med Sci Monit 2016; 22:2714-2719

DOI: 10.12659/MSM.896919

Available online:

Published: 2016-08-01


BACKGROUND: We evaluated the hematological, biochemical, and histopathological effects of Montelukast on pancreatic damage in an experimental acute pancreatitis model created by cerulein in rats before and after the induction of pancreatitis.
MATERIAL AND METHODS: Forty rats were divided into 4 groups with 10 rats each. The study groups were: the Cerulein (C) group, the Cerulein + early Montelukast (CMe) group, the Cerulein + late Montelukast (CMl) group, and the Control group. The pH, pO2, pCO2, HCO3, leukocyte, hematocrit, pancreatic amylase, and lipase values were measured in the arterial blood samples taken immediately before rats were killed.
RESULTS: There were statistically significant differences between the C group and the Control group in the values of pancreatic amylase, lipase, blood leukocyte, hematocrit, pH, pO2, pCO2, HCO3, and pancreatic water content, and also in each of the values of edema, inflammation, vacuolization, necrosis, and total histopathological score (P<0.05). When the CMl group and C group were compared, no statistically significant differences were found in any parameter analyzed. When the CMe group was compared with the C group, pancreatic amylase, lipase, pH, PO2, pCO2, HCO3, pancreatic water content, histopathological edema, inflammation, and total histopathological score values were significantly different between the groups (P<0.05). Finally, when the CMe group and the Control group were compared, significant differences were found in all except 2 (leukocyte and pO2) parameters (P<0.05).
CONCLUSIONS: Leukotriene receptor antagonists used in the late phases of pancreatitis might not result in any benefit; however, when they are given in the early phases or prophylactically, they may decrease pancreatic damage.

Keywords: Amylases - blood, Acetates - pharmacology, Animals, Ceruletide, Disease Models, Animal, Edema - pathology, Leukotriene Antagonists - pharmacology, Lipase - blood, Pancreatitis - drug therapy, Quinolines - pharmacology, Rats, Rats, Sprague-Dawley



Back